Centrus Energy’s stock nearly quadrupled over the past 12 months as investors rotated into nuclear power plays. The company’s market capitalization stands at approximately $5.2 billion, yet it trades at a lofty 72 times forward earnings and 11 times trailing sales. These premium multiples reflect strong enthusiasm for its unique position in both conventional low-enriched uranium (LEU) and high-assay LEU (HALEU) markets, but they could also limit short-term upside unless new catalysts emerge.

After revenues plunged from $1.86 billion in 2012 to $193 million in 2018 amid plant closures and weak uranium prices, Centrus has staged a comeback. From 2018 to 2024, sales grew at a 15% compound annual rate to $442 million, supported by renewed nuclear demand and the launch of HALEU production for government contracts in 2023. Analysts forecast a 7% revenue CAGR to $538 million by 2027, while the global HALEU market is projected to expand near 22% annually through 2033—pointing to accelerating growth once advanced reactor projects scale up.

In early January 2026, Centrus received a $900 million award from the U.S. Department of Energy to expand its uranium enrichment facilities toward commercial-scale HALEU output. This funding elevates Centrus as the only public U.S. producer of HALEU, a critical fuel for next-generation small modular and advanced reactors. The infusion de-risks its capital plan and underpins its medium-term target to capture a majority share of emerging HALEU supply contracts.

Despite the strong operational outlook, Roth Capital analyst Joseph Reagor maintained a neutral stance and raised his 12-month price target, which nonetheless implies more than 60% downside from recent levels. The cautious rating highlights that much of Centrus’s anticipated growth may already be priced in, suggesting that without a substantial re-rating or additional government or utility contracts, the stock could trade in a range rather than resume its spectacular ascent.